Attovia Therapeutics, Inc. (ATTO) stock
ATTONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026
$14.86+0.13 (+0.92%)
Close on Nov 17, 2026Market cap $678.38MP/E –Yield –
Attovia Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$25.67M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.16M | – |
See a number that looks wrong?